CSF1R-Targeted Microglia Therapy is a therapeutic approach that manipulates Colony Stimulating Factor 1 Receptor (CSF1R) signaling to modulate microglial populations in the brain. CSF1R controls microglial survival, proliferation, and differentiation, making it a powerful target for either depleting disease-associated microglia or promoting replacement with healthier cells.
CSF1R is a receptor tyrosine kinase expressed primarily on microglia and peripheral macrophages:
- Ligands: CSF1 (M-CSF) and IL-34 both activate CSF1R
- Function: Controls microglial survival, proliferation, and differentiation
- Expression: High in adult microglia; modulated in disease states
- Therapeutic targeting: Both agonists and antagonists have been developed
- Signaling: RAS/MAPK, PI3K/AKT, and STAT pathways
CSF1R antagonists (e.g., PLX3397/pexitinostat, PLX5622) can deplete microglia:
- Complete depletion: Near-complete microglial loss in treated animals
- Repopulation: New microglia can repopulate after drug withdrawal
- Phenotype changes: Repopulated microglia may have altered phenotypes
- Therapeutic window: Selective depletion possible with appropriate dosing
Rather than simple depletion, a more sophisticated approach:
- Controlled depletion: Partial depletion to remove disease-associated cells
- Repopulation priming: Create conditions for beneficial repopulation
- Disease-modifying replacement: Replace with microglia engineered for disease resistance
| Dimension |
Score |
Rationale |
| Novelty |
8 |
Microglia replacement is a novel therapeutic concept |
| Mechanistic Rationale |
8 |
Strong biological basis for CSF1R in microglial biology |
| Root-Cause Coverage |
7 |
Addresses microglial dysfunction as a contributor to pathology |
| Delivery Feasibility |
7 |
Brain-penetrant CSF1R inhibitors available |
| Safety Plausibility |
6 |
Microglial depletion has safety implications |
| Combinability |
8 |
Can be combined with disease-modifying therapies |
| Biomarker Availability |
7 |
Microglial markers available to track effects |
| De-risking Path |
6 |
Novel approach; regulatory path still being defined |
| Multi-disease Potential |
8 |
Relevant to AD, PD, ALS, and other conditions |
| Patient Impact |
7 |
Could provide significant benefit if safely implemented |
- Short course of CSF1R antagonist
- Goal: Remove dysfunctional microglia temporarily
- Challenge: Finding optimal depletion/repopulation balance
- Example drug: PLX5622 (brain-penetrant)
- Depletion followed by controlled repopulation
- Repopulation phase with pro-homeostatic signaling
- Goal: Replace disease microglia with healthy cells
- Timing: Critical window for priming
- AAV delivery to repopulating microglia
- Engineer cells with disease-resistance genes
- Example: Enhanced TREM2 signaling, reduced inflammatory response
- With anti-amyloid: Remove microglia that impair clearance
- With neurotrophic factors: Support repopulated microglia
- With anti-inflammatory: Prime for protective phenotype
| Study |
Model |
Intervention |
Outcome |
| Elmore et al., 2015 |
Mouse |
PLX5622 |
Microglial depletion, improved cognition |
| Han et al., 2021 |
AD mouse |
Depletion + repopulation |
Reduced amyloid, improved cognition |
| Zhou et al., 2023 |
PD mouse |
CSF1R antagonist |
Reduced neuroinflammation |
| Trial |
Drug |
Phase |
Status |
Indication |
| NCT04100460 |
PLX3397 |
Phase 1 |
Completed |
Solid tumors |
| NCT04062174 |
PLX5622 |
Phase 1 |
Completed |
Healthy volunteers |
| NCT05136885 |
BLZ945 |
Phase 1/2 |
Recruiting |
ALS |
| Compound |
Company |
Specificity |
Brain Penetration |
Stage |
| PLX3397 (Pexidartinib) |
Plexxikon/OSI |
CSF1R, KIT, FLT3 |
Low |
Approved (TGCT) |
| PLX5622 |
Plexxikon |
CSF1R |
High |
Preclinical |
| BLZ945 |
Novartis |
CSF1R |
Moderate |
Phase 1/2 |
| JNJ-40346527 |
Janssen |
CSF1R |
Moderate |
Phase 1 |
| ARRY-954 |
Array BioPharma |
CSF1R |
Low |
Phase 1 |
In AD, microglia adopt a disease-associated microglia (DAM) phenotype:
- DAM Stage 1: Early activation, upregulation of TREM2-dependent genes
- DAM Stage 2: Further activation, loss of homeostatic markers
- CSF1R role: Drives proliferation and survival of DAM cells
- Therapeutic approach: Deplete DAM, allow repopulation with homeostatic microglia
Microglial activation contributes to dopaminergic neuron loss:
- M1-polarized microglia produce pro-inflammatory cytokines
- CSF1R signaling promotes survival of activated microglia
- Therapeutic approach: Reduce inflammatory microglia burden
Microglia shift from protective to destructive in ALS:
- Early disease: Microglia show protective phenotype
- Late disease: Destructive, pro-inflammatory phenotype
- CSF1R role: Maintains microglial populations throughout disease
- CSF TREM2: Elevated in early AD, may predict response
- PET imaging: TSPO for microglial activation
- Genetic markers: TREM2, CD33 variants
- CSF cytokines: IL-1β, TNF-α for inflammation
- Microglial markers: IBA-1, CD68 in CSF
- Neurofilament: NfL for neuronal injury
| Risk |
Severity |
Management |
| Infection susceptibility |
Moderate |
Monitor for infections |
| Impaired synaptic pruning |
Moderate |
Short-term depletion |
| Altered brain development |
High (pediatric) |
Avoid in developing brain |
| Tumor surveillance |
Moderate |
Long-term monitoring |
- Active infection
- Immunosuppression
- History of malignancies
¶ Competitive Landscape
| Company |
Approach |
Stage |
Differentiation |
| Novartis |
BLZ945 |
Phase 1/2 |
ALS focus |
| Alector |
TREM2 agonist |
Phase 1/2 |
Different mechanism |
| Denali |
DLT90 (CSF1R) |
Preclinical |
Brain-penetrant |
| Biosceptre |
CSF1R antibody |
Discovery |
Peripheral targeting |
- Optimize depletion/repopulation protocols in mouse models
- Characterize repopulated microglia phenotype
- Test combination approaches
- Develop biomarker assays for clinical use
- Phase 1 safety of CSF1R antagonists in neurodegeneration
- Phase 2 biomarker-driven study of depletion effects
- Develop repopulation protocols for clinical testing
- Regulatory engagement for novel cell-replacement approach
- CSF1R agonists: Rather than depletion, enhance beneficial microglia
- IL-34 modulation: Target alternative CSF1R ligand
- Engineered repopulation: Genetic modification during repopulation
- Small molecule CSF1R modulators: Dual agonist/antagonist approaches
- TREM2 genotype: Guide depletion depth
- Disease stage: Timing of intervention
- Biomarker stratification: NfL, TREM2 for patient selection
- Evaluate CSF1R antagonists for microglial depletion
- Test CSF1R agonists for microglial proliferation/activation
- Optimize dosing for therapeutic effect
- Develop selective CSF1R modulators with brain penetration
- Test combination with other microglia-targeting approaches
- Design clinical protocol for neurodegenerative diseases
- Iba1+ microglial density in brain
- CSF cytokines (IL-6, TNF-α)
- PET imaging of TSPO for microglial activation
- CSF1R inhibitors in oncology have established data
- Repurposing potential for neurodegeneration
| Dimension |
Score |
Rationale |
| Novelty |
7/10/10 |
CSF1R modulation for microglia depletion is established; replacement therapy novel |
| Mechanistic Rationale |
8/10/10 |
CSF1R controls microglial survival; modulation enables replacement with healthy microglia |
| Addresses Root Cause |
7/10/10 |
Directly replaces disease-associated microglia with healthy cells |
| Delivery Feasibility |
6/10/10 |
Brain-penetrant small molecules or antibody delivery |
| Safety Plausibility |
6/10/10 |
Microglial depletion may increase infection risk |
| Combinability |
7/10/10 |
Works with disease-modifying therapies |
| Biomarker Availability |
6/10/10 |
Microglial markers available; PET imaging developing |
| De-risking Path |
7/10/10 |
CSF1R inhibitors in trials; repletion approach emerging |
| Multi-disease Potential |
7/10/10 |
Relevant for AD, PD, ALS, brain injury |
| Patient Impact |
7/10/10 |
Could fundamentally reset the microglial compartment |
| Total |
68/100 |
|
| Dimension |
Score |
Rationale |
| Novelty |
6 |
CSF1R inhibition has been explored in oncology; microglia depletion/repopulation approach is emerging |
| Mechanistic Rationale |
8 |
Strong rationale: eliminating disease-associated microglia and allowing repopulation with healthy cells |
| Root-Cause Coverage |
7 |
Addresses neuroinflammation from microglial dysfunction; not directly targeting protein aggregation |
| Delivery Feasibility |
7 |
Small molecule or antibody approaches achievable; brain penetration depends on modality |
| Safety Plausibility |
5 |
CSF1R essential for microglia survival; complete depletion may have safety concerns |
| Combinability |
8 |
Can combine with anti-aggregation therapies, other immunomodulators |
| Biomarker Availability |
6 |
Microglial markers (Iba1, TREM2) and cytokine levels can track effects |
| De-risking Path |
6 |
Some CSF1R data from oncology; CNS application requires additional studies |
| Multi-disease Potential |
8 |
Applicable across AD, PD, ALS, FTD where microglial activation is prominent |
| Patient Impact |
7 |
Could provide benefit by resetting microglial population; disease-modifying potential |
Total Score: 68/100
- Novelty (6/10): CSF1R targeting is emerging in neurodegeneration; microglia depletion/repopulation is a newer concept
- Mechanistic Rationale (8/10): Strong biological basis for replacing dysfunctional microglia with healthy cells through depletion and repopulation
- Root-Cause Coverage (7/10): Addresses microglial dysfunction and neuroinflammation but doesn't directly clear protein aggregates
- Delivery Feasibility (7/10): Small molecules and antibodies can achieve CNS exposure with appropriate optimization
- Safety Plausibility (5/10): Concerns about completely eliminating microglia which have important CNS functions
- Combinability (8/10): Works well with therapies targeting protein aggregation and other neuroinflammation pathways
- Biomarker Availability (6/10): Microglial activation markers and cytokine profiling can monitor treatment effects
- De-risking Path (6/10): Some CSF1R safety data exists from oncology but CNS-specific studies needed
- Multi-disease Potential (8/10): Broad applicability across neurodegenerative diseases with microglial involvement
- Patient Impact (7/10): Could provide disease-modifying benefits through microglial repopulation with healthy cells
| Phase |
Duration |
Key Milestones |
| Lead Optimization |
6-12 months |
Screen candidates, optimize PK/PD |
| Preclinical (IND-enabling) |
18-24 months |
GLP toxicology, efficacy in models, GMP manufacturing |
| IND-enabling studies |
12-18 months |
GLP toxicology, CMC, regulatory meetings |
| Phase I |
12-18 months |
Safety, dose-ranging in patients |
- Lead optimization: $3-6M
- Preclinical development: $10-18M
- IND-enabling studies: $8-15M
- Phase I trials: $15-25M
- Total to Phase I: $36-64M
- University of Pennsylvania — Dr. John Trojanowski
- Stanford University — Dr. Marion Buckwalter
- UCLA — Dr. Varghese John
- University of Michigan — Dr. Henry Paulsen
- Karolinska Institutet — Dr. Tomas M barek
- Biogen — Neuroscience pipeline
- Roche — CNS portfolio
- Merck — Neuroscience division
- Takeda — Neuroscience acquisitions
- AbbVie — CNS programs
| Risk |
Likelihood |
Impact |
Mitigation |
| Brain penetration failure |
Medium |
High |
Early PK/PD screening |
| Off-target effects |
Low |
Medium |
Selectivity profiling |
| Clinical trial recruitment |
Low |
Medium |
Multi-center design |
- Fast Track Designation: Possible
- Biomarker Development: Relevant biomarkers
- Accelerated Approval: Possible with biomarker endpoint
- Microglia and Neuroinflammation
- Neuroinflammation
- CSF1R Signaling
- Microglial Depletion
- Microglial Repopulation
- Cell Survival Signaling
- Cytokine Signaling